Cover Image
Market Research Report
Product code
1003247

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026

Published: | MarketsandMarkets | 155 Pages | Delivery time: 1-2 business days

Price

Back to Top
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026
Published: April 28, 2021
MarketsandMarkets
Content info: 155 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period. Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.

"The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, bytype, during the forecast period"

The stem cell therapy market is segmented intoallogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing Alaogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.

"Bone Marrow-derived MSCssegment accounted for the highest CAGR"

Based on the cell source from which stem cells are obtained, the global stem cell therapy market is

segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.

"Asia Pacific: The fastest-growing countryin thestem cell therapy market"

Thestem cell therapy market is segmented into North America, Europe, Asia Pacific,RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%and Demand Side 20%
  • By Designation: C-level - 25%, D-level - 20%, and Others - 55%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

  • Smith & Nephew (UK)
  • MEDIPOST (South Korea)
  • Anterogen (South Korea)
  • CORESTEM (South Korea)
  • PHARMICELL (South Korea)
  • NuVasive (US)
  • RTI Surgical (US)
  • AlloSource (US)
  • JCR Pharmaceuticals (Japan)
  • Takeda Pharmaceutical Company (Japan)
  • HolostemTerapieAvanzateS.r.l (Italy)
  • Orthofix (US)
  • Regrow Biosciences (India)
  • Stempeutics Research (India)
  • Athersys (US),
  • Mesoblast (Australia),
  • BioRestorative Therapies (US)
  • Pluristem Therapeutics (Israel)
  • BrainStorm Cell Therapeutics (US)
  • ViaCyte (US)
  • Kangstem Biotech (South Korea)
  • Hope Biosciences (US)
  • Cellular Biomedicine Group (US)
  • and Personalized Stem Cells (US)

Research Coverage:

This report provides a detailed picture of thestem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

Table of Contents
Product Code: BT 5049

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET SCOPE
    • 1.2.1 MARKETS COVERED
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET
    • 2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
    • FIGURE 3 DATA TRIANGULATION METHODOLOGY
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP)
    • FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP DOWN)
    • FIGURE 6 STEM CELL THERAPY MARKET SIZE (USD MILLION): FINAL MARKET SIZE
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
    • FIGURE 8 FINAL CAGR PROJECTIONS (2021-2026)
  • 2.4 INSIGHTS FROM PRIMARIES
    • FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 10 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2020
    • FIGURE 11 STEM CELL THERAPY MARKET SHARE, BY CELL SOURCE, 2020
    • FIGURE 12 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE STEM CELL THERAPY MARKET

4 PREMIUM INSIGHTS

  • 4.1 STEM CELL THERAPY MARKET OVERVIEW
    • FIGURE 14 INCREASING INVESTMENTS & FUNDING FOR STEM CELL RESEARCH IS A KEY FACTOR DRIVING MARKET GROWTH
  • 4.2 NORTH AMERICA: STEM CELL THERAPY MARKET
    • FIGURE 15 ALLOGENEIC STEM CELL THERAPY TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN STEM CELL THERAPY MARKET
  • 4.3 STEM CELL THERAPY MARKET, BY CELL SOURCE
    • FIGURE 16 BONE MARROW-DERIVED MSCS TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • 4.4 STEM CELL THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 STEM CELL THERAPY MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Availability of funding for stem cell research
    • FIGURE 19 STEM CELL RESEARCH FUNDING IN THE LAST 10 YEARS
    • TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016-2021 (USD MILLION)
      • 5.2.1.2 Increasing GMP-certification approvals for cell therapy production facilities
    • TABLE 3 RECENT DEVELOPMENTS
      • 5.2.1.3 Increasing clinical trials for stem cell based-therapies
    • FIGURE 20 NUMBER OF CLINICAL TRIALS (2015-2020)
    • FIGURE 21 CLINICAL TRIALS, BY PHASE
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Ethical concerns related to embryonic stem cells
      • 5.2.2.2 High cost of cell-based research
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 The emergence of iPSCs as an alternative to ESCs
      • 5.2.3.2 Growing demand for cell & gene therapies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical limitations
  • 5.3 COVID-19 IMPACT ANALYSIS
    • FIGURE 22 NUMBER OF CLINICAL TRIALS FOR COVID-19
    • FIGURE 23 CLINICAL TRIALS FOR COVID-19, BY COUNTRY
  • 5.4 TECHNOLOGY ANALYSIS
    • TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS OF THE STEM CELL THERAPY MARKET
  • 5.6 ECOSYSTEM MARKET MAP
    • FIGURE 25 ECOSYSTEM OF THE STEM CELL THERAPY MARKET
  • 5.7 SUPPLY CHAIN
    • FIGURE 26 SUPPLY CHAIN OF STEM CELL THERAPY MARKET
  • 5.8 PORTERS FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITION RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 NORTH AMERICA
    • TABLE 5 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
    • 5.9.2 EUROPE
    • TABLE 6 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
    • 5.9.3 ASIA PACIFIC
    • TABLE 7 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
    • 5.9.4 ROW
    • TABLE 8 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
  • 5.10 PRICING ANALYSIS
    • TABLE 9 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
  • 5.11 PATENT ANALYSIS
    • FIGURE 27 PATENT ANALYSIS OF STEM CELL THERAPY IN THE LAST 10 YEARS (2011-2020)

6 STEM CELL THERAPY MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 10 STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 6.2 ALLOGENEIC STEM CELL THERAPY
    • 6.2.1 EASE IN PRODUCTION PROCESSES TO DRIVE MARKET GROWTH
    • TABLE 11 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 12 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 13 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 14 APAC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 AUTOLOGOUS STEM CELL THERAPY
    • 6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE THE MARKET GROWTH
    • TABLE 15 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 16 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 17 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 18 APAC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 STEM CELL THERAPY MARKET, BY CELL SOURCE

  • 7.1 INTRODUCTION
    • TABLE 19 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
  • 7.2 ADIPOSE TISSUE-DERIVED MSCS
    • 7.2.1 ADVANTAGES OF BEING EASY TO ISOLATE AND HARVEST DRIVES THE MARKET GROWTH OF THIS SEGMENT
    • TABLE 20 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 21 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 22 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 23 APAC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 BONE MARROW-DERIVED MSCS
    • 7.3.1 INCREASING CASES OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH OF THIS SEGMENT
    • TABLE 24 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 25 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 26 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 27 APAC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS
    • 7.4.1 LOW CHANCES OF REJECTION FROM THE IMMUNE SYSTEM IS LIKELY TO SUPPORT MARKET GROWTH OF THIS SEGMENT
    • TABLE 28 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 29 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 30 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 31 APAC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 OTHER CELL SOURCES
    • TABLE 32 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2019-2026 (USD MILLION)

8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 34 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
  • 8.2 MUSCULOSKELETAL DISORDERS
    • 8.2.1 INCREASING CASES OF OSTEOARTHRITIS TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
    • TABLE 35 MUSCULOSKELETAL DISORDERS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 36 NORTH AMERICA: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 37 EUROPE: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 38 APAC: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 WOUNDS & INJURIES
    • 8.3.1 INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT THE MARKET GROWTH
    • TABLE 39 WOUNDS & INJURIES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 40 NORTH AMERICA: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 41 EUROPE: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 42 APAC: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
    • 8.4.1 INCREASING CLINICAL TRIALS FOR THIS SEGMENT IS LIKELY TO SUPPORT MARKET GROWTH
    • TABLE 43 INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY REGION, 2019-2026, (USD MILLION)
    • TABLE 44 NORTH AMERICA: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 45 EUROPE: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 46 APAC: INFLAMMATORY & INFLAMMATORY DISEASES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.5 SURGERIES
    • 8.5.1 INCREASING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH
    • TABLE 47 SURGERIES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 48 NORTH AMERICA: SURGERIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 49 EUROPE: SURGERIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 50 APAC: SURGERIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.6 CARDIOVASCULAR DISEASES
    • 8.6.1 INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH IS LIKELY TO SUPPORT MARKET GROWTH
    • TABLE 51 CARDIOVASCULAR DISEASES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 52 NORTH AMERICA: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 53 EUROPE: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 54 APAC: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.7 NEUROLOGICAL DISORDERS
    • 8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS SUPPORTS MARKET GROWTH OF THIS SEGMENT
    • TABLE 55 NEUROLOGICAL DISORDERS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 56 NORTH AMERICA: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 57 EUROPE: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 58 APAC: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.8 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 59 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 60 NORTH AMERICA: OTHER THERAPEUTIC APPLICATIONS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

9 STEM CELL THERAPY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • FIGURE 28 STEM CELL THERAPY MARKET SNAPSHOT
    • TABLE 61 STEM CELL THERAPY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 29 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
    • TABLE 62 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 64 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Increasing investments and funding for stem cell research drive the market growth in the UK
    • FIGURE 30 NIH FUNDING IN THE LAST 10 YEARS (2011-2021)
    • TABLE 66 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 67 US: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 68 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Rising approvals of stem cell therapies in Canada are likely to boost the market
    • TABLE 69 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 70 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 71 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 72 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 73 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 74 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 75 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Strong R&D base and focus on minimally invasive surgeries to drive market growth in Germany
    • TABLE 76 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 77 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 78 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 The rising adoption of cell-based therapies in the UK drives the market growth
    • TABLE 79 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 80 UK: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 81 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Rising healthcare expenditure is likely to drive market growth in France for stem cell therapy
    • TABLE 82 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 83 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 84 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.3.4 REST OF EUROPE
    • TABLE 85 ROE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 86 ROE: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 87 ROE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
    • TABLE 88 APAC: STEM CELL THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 89 APAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 90 APAC: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 91 APAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Growing geriatric population and faster regulatory approval process is expected to augment market growth in Japan
    • TABLE 92 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE 2019-2026 (USD MILLION)
    • TABLE 93 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 94 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.4.2 SOUTH KOREA
      • 9.4.2.1 The presence of major players supports market growth in South Korea
    • TABLE 95 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 96 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 97 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Rising number of neurodegenerative disorders to drive market growth in India
    • TABLE 98 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 99 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 100 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 101 ROAPAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 102 ROAPAC: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 103 ROAPAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)
  • 9.5 REST OF THE WORLD
    • TABLE 104 ROW: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2026 (USD MILLION)
    • TABLE 105 ROW: STEM CELL THERAPY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 106 ROW: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 32 TOP MARKET PLAYERS DOMINATE THE STEM CELL THERAPY MARKET
  • 10.3 MARKET SHARE ANALYSIS
    • FIGURE 33 STEM CELL THERAPY MARKET RANK, BY KEY PLAYER (2020)
    • TABLE 107 STEM CELL THERAPY MARKET: DEGREE OF COMPETITION
  • 10.4 COMPETITIVE LEADERSHIP MAPPING
    • 10.4.1 STARS
    • 10.4.2 EMERGING LEADERS
    • 10.4.3 PERVASIVE PLAYERS
    • 10.4.4 PARTICIPANTS
    • FIGURE 34 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT (2020)- APPROVED PRODUCTS
  • 10.5 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE)
    • 10.5.1 PROGRESSIVE COMPANIES
    • 10.5.2 STARTING BLOCKS
    • 10.5.3 RESPONSIVE COMPANIES
    • 10.5.4 DYNAMIC COMPANIES
    • FIGURE 35 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE)
  • 10.6 COMPANY PRODUCT FOOTPRINT
    • FIGURE 36 PRODUCT PORTFOLIO ANALYSIS BY APPLICATION: STEM CELL THERAPY MARKET
  • 10.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE STEM CELL THERAPY MARKET
    • FIGURE 37 GEOGRAPHIC REVENUE MIX: STEM CELL THERAPY MARKET (2020)
  • 10.8 COMPETITIVE SCENARIO
    • 10.8.1 PRODUCT LAUNCHES
    • 10.8.2 DEALS
    • TABLE 109 STEM CELL THERAPY MARKET: DEALS, MARCH 2019-JANUARY 2021
    • 10.8.3 OTHER DEVELOPMENTS
    • TABLE 110 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS (MAY 2019-NOVEMBER 2020)

11 COMPANY PROFILES

  • 11.1 MAJOR PLAYERS
  • (Business Overview, Products Offered, Recent Developments, MnM View)**
    • 11.1.1 SMITH & NEPHEW
    • TABLE 111 SMITH & NEPHEW: BUSINESS OVERVIEW
    • FIGURE 38 SMITH & NEPHEW: COMPANY SNAPSHOT (2020)
    • TABLE 112 SMITH & NEPHEW : PRODUCTS OFFERED
    • 11.1.2 MEDIPOST
    • TABLE 113 MEDIPOST : BUSINESS OVERVIEW
    • FIGURE 39 MEDIPOST: COMPANY SNAPSHOT (2019)
    • TABLE 114 MEDIPOST : PRODUCTS OFFERED
    • 11.1.3 ANTEROGEN
    • TABLE 115 ANTEROGEN: BUSINESS OVERVIEW
    • TABLE 116 ANTEROGEN: PRODUCTS OFFERED
    • 11.1.4 CORESTEM
    • TABLE 117 CORESTEM : BUSINESS OVERVIEW
    • TABLE 118 CORESTEM: PRODUCTS OFFERED
    • 11.1.5 PHARMICELL
    • TABLE 119 PHARMICELL : BUSINESS OVERVIEW
    • TABLE 120 PHARMICELL: PRODUCTS OFFERED
    • 11.1.6 NUVASIVE
    • TABLE 121 NUVASIVE: BUSINESS OVERVIEW
    • FIGURE 40 NUVASIVE: COMPANY SNAPSHOT (2020)
    • TABLE 122 NUVASIVE: PRODUCTS OFFERED
    • 11.1.7 RTI SURGICAL
    • TABLE 123 RTI SURGICAL : BUSINESS OVERVIEW
    • TABLE 124 RTI SURGICAL: PRODUCTS OFFERED
    • 11.1.8 ALLOSOURCE
    • TABLE 125 ALLOSOURCE: BUSINESS OVERVIEW
    • TABLE 126 ALLOSOURCE: PRODUCTS OFFERED
    • 11.1.9 JCR PHARMACEUTICALS
    • TABLE 127 JCR PHARMACEUTICALS: BUSINESS OVERVIEW
    • FIGURE 41 JCR PHARMACEUTICALS: COMPANY SNAPSHOT (2019)
    • TABLE 128 JCR PHARMACEUTICALS: PRODUCTS OFFERED
    • 11.1.10 TAKEDA PHARMACEUTICAL COMPANY
    • TABLE 129 TAKEDA PHARMACEUTICAL COMPANY: BUSINESS OVERVIEW
    • FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY: COMPANY SNAPSHOT (2019)
    • TABLE 130 TAKEDA PHARMACEUTICAL COMPANY: PRODUCTS OFFERED
    • 11.1.11 HOLOSTEM TERAPIE AVANZATE
    • TABLE 131 HOLOSTEM TERAPIE AVANZATE : BUSINESS OVERVIEW
    • TABLE 132 HOLOSTEM TERAPIE AVANZATE : PRODUCTS OFFERED
    • 11.1.12 ORTHOFIX
    • TABLE 133 ORTHOFIX : BUSINESS OVERVIEW
    • FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2019)
    • TABLE 134 ORTHOFIX: PRODUCTS OFFERED
    • 11.1.13 STEMPEUTICS RESEARCH
    • 11.1.14 REGROW BIOSCIENCES
  • 11.2 OTHER PLAYERS (UNDER PIPELINE)
    • 11.2.1 ATHERSYS
    • TABLE 135 ATHERSYS: BUSINESS OVERVIEW
    • FIGURE 44 ATHERSYS: COMPANY SNAPSHOT (2019)
    • TABLE 136 ATHERSYS: PRODUCTS OFFERED
    • 11.2.2 MESOBLAST
    • TABLE 137 MESOBLAST: BUSINESS OVERVIEW
    • FIGURE 45 MESOBLAST: COMPANY SNAPSHOT (2020)
    • TABLE 138 MESOBLAST: PRODUCTS OFFERED
    • 11.2.3 BIORESTORATIVE THERAPIES
    • TABLE 139 BIORESTORATIVE THERAPIES : BUSINESS OVERVIEW
    • TABLE 140 BIORESTORATIVE THERAPIES: PRODUCTS OFFERED
    • 11.2.4 PLURISTEM THERAPUTICS
    • TABLE 141 PLURISTEM THERAPIES: BUSINESS OVERVIEW
    • TABLE 142 PLURISTEM THERAPIES: PRODUCTS OFFERED
    • 11.2.5 BRAINSTORM CELL THERAPEUTICS
    • 11.2.6 GAMIDA CELL
    • 11.2.7 VIACYTE
    • 11.2.8 KANGSTEM BIOTECH
    • 11.2.9 HOPE BIOSCIENCES
    • 11.2.10 CELLULAR BIOMEDICINE GROUP
    • 11.2.11 PERSONALIZED STEM CELLS
  • *Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS